<?xml version="1.0" encoding="UTF-8"?><OAI-PMH
	xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2019-03-02T19:49:08Z</responseDate><request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:3704157" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request><GetRecord><record><header><identifier>oai:pubmedcentral.nih.gov:3704157</identifier><datestamp>2014-01-01</datestamp><setSpec>nihpa</setSpec><setSpec>pmc-open</setSpec><setSpec>manuscript</setSpec></header><metadata><article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.0/ https://jats.nlm.nih.gov/archiving/1.0/xsd/JATS-archivearticle1.xsd" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-journal-id">9216904</journal-id>
      <journal-id journal-id-type="pubmed-jr-id">2419</journal-id>
      <journal-id journal-id-type="nlm-ta">Nat Genet</journal-id>
      <journal-id journal-id-type="iso-abbrev">Nat. Genet.</journal-id>
      <journal-title-group>
        <journal-title>Nature genetics</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1061-4036</issn>
      <issn pub-type="epub">1546-1718</issn>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="accession">PMC3704157</article-id>
      <article-id pub-id-type="pmcid">PMC3704157</article-id>
      <article-id pub-id-type="pmc-uid">3704157</article-id>
      <article-id pub-id-type="pmid">23708187</article-id>
      <article-id pub-id-type="pmid">23708187</article-id>
      <article-id pub-id-type="doi">10.1038/ng.2646</article-id>
      <article-id pub-id-type="manuscript">nihpa474984</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Targeted resequencing in epileptic encephalopathies identifies <italic>de novo</italic> mutations in <italic>CHD2</italic> and <italic>SYNGAP1</italic></article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Carvill</surname>
            <given-names>Gemma L.</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Heavin</surname>
            <given-names>SinÃ©ad B.</given-names>
          </name>
          <xref ref-type="aff" rid="A2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Yendle</surname>
            <given-names>Simone C.</given-names>
          </name>
          <xref ref-type="aff" rid="A2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>McMahon</surname>
            <given-names>Jacinta M.</given-names>
          </name>
          <xref ref-type="aff" rid="A2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>OâRoak</surname>
            <given-names>Brian J.</given-names>
          </name>
          <xref ref-type="aff" rid="A3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Cook</surname>
            <given-names>Joseph</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Khan</surname>
            <given-names>Adiba</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Dorschner</surname>
            <given-names>Michael O</given-names>
          </name>
          <xref ref-type="aff" rid="A4">4</xref>
          <xref ref-type="aff" rid="A5">5</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Weaver</surname>
            <given-names>Molly</given-names>
          </name>
          <xref ref-type="aff" rid="A4">4</xref>
          <xref ref-type="aff" rid="A5">5</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Calvert</surname>
            <given-names>Sophie</given-names>
          </name>
          <xref ref-type="aff" rid="A6">6</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Malone</surname>
            <given-names>Stephen</given-names>
          </name>
          <xref ref-type="aff" rid="A6">6</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Wallace</surname>
            <given-names>Geoffrey</given-names>
          </name>
          <xref ref-type="aff" rid="A6">6</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Stanley</surname>
            <given-names>Thorsten</given-names>
          </name>
          <xref ref-type="aff" rid="A7">7</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Bye</surname>
            <given-names>Ann M. E.</given-names>
          </name>
          <xref ref-type="aff" rid="A8">8</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Bleasel</surname>
            <given-names>Andrew</given-names>
          </name>
          <xref ref-type="aff" rid="A9">9</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Howell</surname>
            <given-names>Katherine B.</given-names>
          </name>
          <xref ref-type="aff" rid="A10">10</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kivity</surname>
            <given-names>Sara</given-names>
          </name>
          <xref ref-type="aff" rid="A11">11</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Mackay</surname>
            <given-names>Mark T.</given-names>
          </name>
          <xref ref-type="aff" rid="A10">10</xref>
          <xref ref-type="aff" rid="A12">12</xref>
          <xref ref-type="aff" rid="A13">13</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Rodriguez-Casero</surname>
            <given-names>Victoria</given-names>
          </name>
          <xref ref-type="aff" rid="A14">14</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Webster</surname>
            <given-names>Richard</given-names>
          </name>
          <xref ref-type="aff" rid="A15">15</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Korczyn</surname>
            <given-names>Amos</given-names>
          </name>
          <xref ref-type="aff" rid="A16">16</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Afawi</surname>
            <given-names>Zaid</given-names>
          </name>
          <xref ref-type="aff" rid="A17">17</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Zelnick</surname>
            <given-names>Nathanel</given-names>
          </name>
          <xref ref-type="aff" rid="A18">18</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lerman-Sagie</surname>
            <given-names>Tally</given-names>
          </name>
          <xref ref-type="aff" rid="A19">19</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lev</surname>
            <given-names>Dorit</given-names>
          </name>
          <xref ref-type="aff" rid="A19">19</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>MÃ¸ller</surname>
            <given-names>Rikke S.</given-names>
          </name>
          <xref ref-type="aff" rid="A20">20</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Gill</surname>
            <given-names>Deepak</given-names>
          </name>
          <xref ref-type="aff" rid="A15">15</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Andrade</surname>
            <given-names>Danielle M.</given-names>
          </name>
          <xref ref-type="aff" rid="A21">21</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Freeman</surname>
            <given-names>Jeremy L.</given-names>
          </name>
          <xref ref-type="aff" rid="A10">10</xref>
          <xref ref-type="aff" rid="A12">12</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Sadleir</surname>
            <given-names>Lynette G.</given-names>
          </name>
          <xref ref-type="aff" rid="A7">7</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Shendure</surname>
            <given-names>Jay</given-names>
          </name>
          <xref ref-type="aff" rid="A3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Berkovic</surname>
            <given-names>Samuel F.</given-names>
          </name>
          <xref ref-type="aff" rid="A2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Scheffer</surname>
            <given-names>Ingrid E.</given-names>
          </name>
          <xref ref-type="aff" rid="A2">2</xref>
          <xref ref-type="aff" rid="A10">10</xref>
          <xref ref-type="aff" rid="A13">13</xref>
          <xref ref-type="aff" rid="A22">22</xref>
          <xref ref-type="corresp" rid="cor1">*</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Mefford</surname>
            <given-names>Heather C.</given-names>
          </name>
          <xref ref-type="aff" rid="A1">1</xref>
          <xref ref-type="corresp" rid="cor1">*</xref>
        </contrib>
      </contrib-group>
      <aff id="A1"><label>1</label>Division of Genetic Medicine, Department of Pediatrics, University of Washington, Seattle, Washington, 98195, USA</aff>
      <aff id="A2"><label>2</label>Epilepsy Research Centre, Department of Medicine, University of Melbourne, Austin Health, Melbourne, Victoria, Australia</aff>
      <aff id="A3"><label>3</label>Department of Genome Sciences, University of Washington, Seattle, Washington, 98195, USA</aff>
      <aff id="A4"><label>4</label>Department of Psychiatry &amp; Behavioral Sciences, University of Washington, Seattle, Washington, 98195, USA</aff>
      <aff id="A5"><label>5</label>Veteran Affairs Puget Sound Health Care System, Seattle, WA 98108, USA</aff>
      <aff id="A6"><label>6</label>Neurosciences Childrenâs Health Queensland, Royal and Mater Childrenâs Hospitals, Brisbane, Queensland, Australia</aff>
      <aff id="A7"><label>7</label>Department of Paediatrics, School of Medicine and Health Sciences, University of Otago, Wellington, New Zealand</aff>
      <aff id="A8"><label>8</label>Department of Paediatric Neurology, University of New South Wales, Sydney Childrenâs Hospital, Sydney, New South Wales, Australia</aff>
      <aff id="A9"><label>9</label>Westmead Hospital, University of Sydney, Sydney, New South Wales, Australia</aff>
      <aff id="A10"><label>10</label>Department of Neurology, The Royal Childrenâs Hospital, Parkville, Melbourne, Victoria, Australia</aff>
      <aff id="A11"><label>11</label>Epilepsy Unit, Schneider Childrenâs Medical Center of Israel, Petach Tikvah, Israel</aff>
      <aff id="A12"><label>12</label>Critical Care &amp; Neurosciences Theme, Murdoch Childrens Research Institute, Melbourne, Victoria, Australia</aff>
      <aff id="A13"><label>13</label>Department of Paediatrics, The University of Melbourne, The Royal Childrenâs Hospital, Melbourne, Victoria, Australia</aff>
      <aff id="A14"><label>14</label>Paediatric Neurology, Monash Medical Centre, Melbourne, Victoria, Australia</aff>
      <aff id="A15"><label>15</label>TY Nelson Department of Neurology, The Children's Hospital at Westmead, Sydney, New South Wales, Australia</aff>
      <aff id="A16"><label>16</label>Department of Neurology, Tel-Aviv University, Tel-Aviv, Israel</aff>
      <aff id="A17"><label>17</label>Tel-Aviv University Medical School, Tel-Aviv, Israel</aff>
      <aff id="A18"><label>18</label>Department of Pediatrics, Carmel Medical Center, Technion Faculty of Medicine, Haifa, Israel</aff>
      <aff id="A19"><label>19</label>Metabolic-Neurogenetic Service, Wolfson Medical Center, Holon, and Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel</aff>
      <aff id="A20"><label>20</label>Danish Epilepsy Centre, Dianalund, Denmark</aff>
      <aff id="A21"><label>21</label>Division of Neurology, Department of Medicine, University of Toronto, Toronto Western Hospital, Krembil Neurosciences Program. Toronto, Canada</aff>
      <aff id="A22"><label>22</label>Florey Institute, Melbourne, Victoria, Australia</aff>
      <author-notes>
        <corresp id="cor1"><label>*</label>To whom correspondence should be addressed: Heather C. Mefford, <email>hmefford@uw.edu</email>; Ingrid E. Scheffer, <email>scheffer@unimelb.edu.au</email></corresp>
      </author-notes>
      <pub-date pub-type="nihms-submitted">
        <day>5</day>
        <month>6</month>
        <year>2013</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>26</day>
        <month>5</month>
        <year>2013</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <month>7</month>
        <year>2013</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>01</day>
        <month>1</month>
        <year>2014</year>
      </pub-date>
      <volume>45</volume>
      <issue>7</issue>
      <fpage>825</fpage>
      <lpage>830</lpage>
      <!--elocation-id from pubmed: 10.1038/ng.2646-->
      <permissions>
        <license>
          <license-p>Users may view, print, copy, download and text and data- mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: <uri xlink:type="simple" xlink:href="http://www.nature.com/authors/editorial_policies/license.html#terms">http://www.nature.com/authors/editorial_policies/license.html#terms</uri></license-p>
        </license>
      </permissions>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro" id="S1">
      <title>Introductory</title>
      <p id="P1">Epileptic encephalopathies are a devastating group of epilepsies with a poor prognosis, for which the majority have unknown etiology. We perform targeted massively parallel resequencing of 19 known and 46 candidate epileptic encephalopathy genes in 500 patients to identify novel genes and investigate the phenotypic spectrum of known genes. Overall, we identify pathogenic mutations in 10% of our cohort. Six of the 46 candidate genes had one or more pathogenic variants, collectively accounting for 3% of our cohort. We show that <italic>de novo CHD2</italic> and <italic>SYNGAP1</italic> mutations are novel causes of epileptic encephalopathies, accounting for 1.2% and 1% of cases respectively. We also further expand the phenotypic spectrum for <italic>SCN1A</italic>, <italic>SCN2A</italic>, and <italic>SCN8A</italic> mutations. To our knowledge, this is the largest cohort of patients with epileptic encephalopathies to undergo targeted resequencing. Implementation of this rapid and efficient method will change diagnosis and understanding of the molecular etiologies of these disorders.</p>
      <p id="P2">Epilepsy is one of the most common neurological disorders with a lifetime incidence of 3%. Epileptic encephalopathies are a devastating group of epilepsies characterized by refractory seizures and cognitive arrest or regression associated with ongoing epileptic activity, and typically carry a poor prognosis<sup><xref rid="R1" ref-type="bibr">1</xref></sup>. <italic>De novo</italic> mutations in several known genes are responsible for some epileptic encephalopathies<sup><xref rid="R2" ref-type="bibr">2</xref></sup>. Furthermore, we and others have shown that rare, <italic>de novo</italic> copy number variants (CNVs) account for up to ~8% of cases<sup><xref rid="R3" ref-type="bibr">3</xref>, <xref rid="R4" ref-type="bibr">4</xref></sup>. Despite this recent progress, making a genetic diagnosis in a patient can be challenging as there is both genetic heterogeneity for a given epilepsy syndrome and phenotypic heterogeneity for a specific gene.</p>
      <p id="P3">The full phenotypic spectrum associated with mutations in known epileptic encephalopathy genes is not known. Very few studies have investigated the role of any given gene across a wide spectrum of epileptic encephalopathy syndromes. This makes serial gene testing in the clinical setting an inefficient and expensive process, after which the vast majority of cases remain unexplained. Furthermore, it is clear that discovery of additional genes that cause epileptic encephalopathies is needed to facilitate genetic diagnosis. Here, we take advantage of a high-throughput targeted sequencing approach to perform comprehensive sequence analysis of 65 genes (19 known genes and 46 candidate genes) (<xref ref-type="supplementary-material" rid="SD1">Supplementary Fig. 1</xref>) in 500 patients with a range of epileptic encephalopathy phenotypes (<xref ref-type="table" rid="T1">Table 1</xref>). Candidate genes were selected from epilepsy-associated CNVs (n=33) or because mutations cause associated neurodevelopmental disorders or other epilepsy syndromes (n=13). Using this approach, we (i) identify novel epileptic encephalopathy genes and (ii) delineate the phenotypic spectrum and mutation frequency for both known and novel epileptic encephalopathy genes.</p>
      <p id="P4">Overall, 91% of the target (65 genes) was sequenced at &gt;25X coverage, required for accurate variant calling (<xref ref-type="supplementary-material" rid="SD1">Supplementary Fig. 2</xref>). We achieved 91% sensitivity across 685 variants (161 loci) from 12 samples that had previously undergone exome sequencing and 100% sensitivity for 24 known variants in previously tested patients; these patients were not included in the discovery cohort.</p>
      <p id="P5">We detected one or more pathogenic or likely pathogenic mutations in six of our 46 candidate genes, with multiple individuals carrying mutations in either of the two novel epileptic encephalopathy genes, <italic>CHD2</italic> (NM_001271.3, NP_001262.3) and <italic>SYNGAP1</italic> (NM_006772.2, NP_006763.2) (<xref ref-type="table" rid="T1">Table 1</xref>, <xref ref-type="table" rid="T2">2</xref>, <xref ref-type="fig" rid="F1">Fig. 1</xref>).</p>
      <p id="P6">Remarkably, we detected six <italic>de novo</italic> variants in the candidate gene, <italic>CHD2</italic> (<xref ref-type="fig" rid="F1">Fig. 1</xref>,<xref ref-type="fig" rid="F2">2</xref>), selected from within the critical interval of 15q26.1 deletions detected in patients with a range of epileptic encephalopathies (<xref ref-type="supplementary-material" rid="SD1">Supplementary Fig. 3</xref>)<sup><xref rid="R5" ref-type="bibr">5</xref>, <xref rid="R6" ref-type="bibr">6</xref></sup>. Four mutations lead to premature truncation of CHD2 (<xref ref-type="table" rid="T2">Table 2</xref>). Two <italic>de novo</italic> missense variants disrupt highly conserved residues within the SNF2-related helicase/ATPase domain (p.Trp548Arg and p.Leu823Pro), and are predicted to be damaging by both PolyPhen2 and SIFT. <italic>CHD2</italic> codes for a member of the chromodomain helicase DNA-binding family of proteins and is characterized by the presence of chromatin remodeling, chromo (chromatin organization modifier) and SNF2-related helicase/ATPase domains. These domains suggest function of this protein as a chromatin remodeler<sup><xref rid="R7" ref-type="bibr">7</xref></sup>. While functional studies in CHD2 are limited, studies of another CHD protein family member, CHD7, have shown that the helicase domain is responsible for ATP-dependent nucleosome remodeling, an integral process in target gene regulation. Furthermore, <italic>in vivo</italic> studies of human <italic>CHD7</italic> mutations within the helicase domain, which cause CHARGE syndrome, resulted in decreased remodeling ability<sup><xref rid="R8" ref-type="bibr">8</xref></sup>. These results suggest that the two <italic>de novo</italic> missense mutations described here may disrupt CHD2 function in a similar manner, while truncating mutations likely result in haploinsufficiency.</p>
      <p id="P7">The six patients with <italic>CHD2</italic> mutations had distinctive features with a median seizure onset of 18 months (range 1â3 years, <xref ref-type="table" rid="T2">Table 2</xref>): myoclonic seizures in all, photosensitivity in three and all had ID, ranging from moderate to severe. A <italic>de novo CHD2</italic> frameshift mutation was reported in a proband with ID and absence seizures<sup><xref rid="R9" ref-type="bibr">9</xref></sup> and a <italic>de novo</italic> missense mutation in an individual with autism spectrum disorder (ASD)<sup><xref rid="R10" ref-type="bibr">10</xref></sup>. These results suggest that mutations in <italic>CHD2</italic> contribute to a broad spectrum of neurodevelopmental disorders. Notably, recent studies implicate <italic>de novo</italic> mutations in <italic>CHD8</italic> in patients with ASD<sup><xref rid="R11" ref-type="bibr">11</xref></sup>. Interestingly, three genes of the chromodomain family (<italic>CHD2</italic>, <italic>CHD7</italic>, <italic>CHD8</italic>) have now been implicated in disorders that impact the neurodevelopmental system. Further studies of this nine-member gene family will determine the role of each across the spectrum of neurodevelopmental disorders, and provide exciting new avenues of research.</p>
      <p id="P8">We identified nine pathogenic or likely pathogenic variants in four of the 13 âepilepsy-associatedâ genes (<xref ref-type="fig" rid="F1">Fig. 1</xref>). We found five truncating variants in <italic>SYNGAP1</italic> (<xref ref-type="fig" rid="F2">Fig. 2</xref>). Patients with <italic>SYNGAP1</italic> mutations had median seizure onset of 14 months (mean 14 months, range 6 months to 3 years) (<xref ref-type="table" rid="T2">Table 2</xref>). They had multiple seizure types, early developmental delay and subsequent regression. Outcome was poor with moderate to severe ID. <italic>SYNGAP1</italic> mutations have been associated with ID and, although most patients have epilepsy, seizures are typically well controlled<sup><xref rid="R9" ref-type="bibr">9</xref>, <xref rid="R12" ref-type="bibr">12</xref>â<xref rid="R18" ref-type="bibr">18</xref></sup>. Our study represents the first cases of epileptic encephalopathies with <italic>SYNGAP1</italic> mutations. These observations suggest that epilepsy is a core feature of both static and progressive encephalopathies associated with <italic>SYNGAP1</italic> mutations, and carry important implications for diagnostic testing.</p>
      <p id="P9">Variants were identified in three additional âepilepsy associated genesâ. There were two <italic>de novo</italic> variants in <italic>MEF2C</italic> (NM_002397.4, NP_002388.2), a missense variant and a stop-loss variant (p.*464SerExt*?). Furthermore, we found <italic>de novo</italic> pathogenic variants in <italic>MBD5</italic> (NM_018328.4, NP_060798.2) (Thr157Glnfs*4) and <italic>GABRG2</italic> (NM_000816.3, NP_000807.2)(p.Arg323Gln) (<xref ref-type="table" rid="T2">Table 2</xref>).</p>
      <p id="P10">We detected a premature truncation mutation (p.Tyr805*) in the CNV candidate gene, <italic>HNRNPU</italic> (NM_031844.2, NP_114032.2). The p.Tyr805* change arose as a result of two consecutive single nucleotide changes c.471T&gt;C and c.472A&gt;T (<xref ref-type="supplementary-material" rid="SD1">Supplementary Fig. 4</xref>) that occur two amino acids upstream of the termination codon. Neither variant was maternally inherited; paternal DNA was not available. A recent report identified <italic>HNRNPU</italic> as a candidate for the ID and seizure phenotypes of probands with 1q44 microdeletions<sup><xref rid="R19" ref-type="bibr">19</xref></sup>. In addition, a <italic>de novo</italic> splice-site variant was identified in a proband with a complex neurodevelopmental phenotype including epilepsy<sup><xref rid="R20" ref-type="bibr">20</xref></sup>. Collectively, these data suggest that haploinsufficiency of <italic>HNRNPU</italic> is associated with epileptic encephalopathy as well as ID, though further phenotype-genotype correlation will improve our understanding of the <italic>HNRNPU</italic> phenotypic spectrum.</p>
      <p id="P11">We identified 32 variants fulfilling our criteria for pathogenicity and an additional four variants that are likely pathogenic in ten of 19 known epileptic encephalopathy genes (<xref ref-type="fig" rid="F1">Fig. 1</xref>, <xref ref-type="table" rid="T1">Table 1</xref>, <xref ref-type="table" rid="T3">Table 3</xref>). We identified multiple patients with mutations in <italic>STXBP1, CDKL5, SCN1A, SCN2A, PCDH19</italic> and <italic>KCNQ2</italic>, accounting for 69% (36/52) of all mutation-positive individuals in our cohort. We detected an additional 16 rare variants in six of these 19 known genes for which we were unable to conduct segregation analysis; it is probable that a number of these variants are also pathogenic (<xref ref-type="supplementary-material" rid="SD1">Supplementary Table 1</xref>).</p>
      <p id="P12">The phenotypes identified in patients with mutations in known genes are provided (<xref ref-type="table" rid="T3">Table 3</xref>), and for some we expand the known phenotypic spectrum. For example, we identified a homozygous recessive missense mutation in <italic>PNKP</italic> in a single proband with unclassified epileptic encephalopathy. <italic>PNKP</italic> mutations are associated with early infantile epileptic encephalopathy comprising microcephaly, early-onset intractable seizures and developmental delay<sup><xref rid="R21" ref-type="bibr">21</xref></sup>. By contrast, our patient did not have microcephaly (head circumference 50<sup>th</sup> centile) or developmental delay but had normal cognition despite refractory epilepsy with multiple seizure types. Also, three patients with <italic>SCN1A</italic> mutations presented with an epilepsy-aphasia phenotype, of which two also had FS+. <italic>SCN1A</italic> mutations are well known to be associated with genetic epilepsy with febrile seizures plus (GEFS+) but have not previously been reported with epilepsy-aphasia syndromes<sup><xref rid="R22" ref-type="bibr">22</xref>, <xref rid="R23" ref-type="bibr">23</xref></sup>. It is possible that the <italic>SCN1A</italic> mutation is not responsible for the epilepsy-aphasia syndrome but equally it could be a modifier predisposing the individual to this group of epileptic encephalopathies. Further work is warranted to clarify this association, perhaps most effectively with exome-sequencing in these patients.</p>
      <p id="P13">We detected five variants in <italic>SCN2A</italic>, which encodes the Î±2 subunit of the voltage gated sodium channel. To date, the majority of <italic>SCN2A</italic> mutations have been associated with the self-limited autosomal dominant syndrome of benign familial neonatal-infantile seizures (BFNIS)<sup><xref rid="R24" ref-type="bibr">24</xref></sup>. Previously, only three <italic>de novo</italic> variants have been reported in patients with epileptic encephalopathies<sup><xref rid="R25" ref-type="bibr">25</xref>, <xref rid="R26" ref-type="bibr">26</xref></sup>. Interestingly our five cases show similar variability in the range of onset seen in BFNIS with three beginning in the neonatal period (11 hours to 2 days) and two in infancy (6 weeks, 13 months). Two had relatively early offset of seizures at 5 weeks and 7 months. The refractory nature of seizures did not correlate with intellectual outcome, which ranged from mild (2) to severe (3) intellectual disability. We conclude that <italic>SCN2A</italic> is an important contributor to the overall burden of epileptic encephalopathies, accounting for 1% of cases.</p>
      <p id="P14">We also identified a pathogenic missense mutation (p.Leu1290Val) in <italic>SCN8A</italic>. To date, only a single <italic>de novo SCN8A</italic> mutation (p.Asn1768Asp) has been described in a proband with severe epileptic encephalopathy and sudden unexplained death in epilepsy<sup><xref rid="R27" ref-type="bibr">27</xref></sup>. Here we describe a second patient presenting with an epileptic encephalopathy beginning at 18 months. Interestingly, this variant was paternally inherited, though the father was shown to have somatic mosaicism (13% mutant allele) supporting its pathogenic effect as seen in other genetic encephalopathies with parental mosaicism<sup><xref rid="R28" ref-type="bibr">28</xref></sup>.</p>
      <p id="P15">The findings in this large series of patients with hitherto unsolved epileptic encephalopathies allows us to begin to frame the overall genetic architecture of this group of disorders. We identified pathogenic or likely pathogenic mutations in 10% of our cohort, with mutations in 16 genes. However, this mutation rate is likely to be an underestimation of the true contribution of each gene to the overall burden of epileptic encephalopathies. Our cohort excluded patients with previously identified mutations, and we were unable to conduct segregation analysis for a subset of variants we identified, some of which are likely to be pathogenic. Furthermore, as larger numbers of patients with mutations of specific genes are identified, distinctive epileptic encephalopathy phenotypes are likely to emerge. Taken together, with up to 8% rare CNVs in epileptic encephalopathy patients in an earlier analysis of a subset of this series<sup><xref rid="R3" ref-type="bibr">3</xref></sup>, we can now collectively ascribe causality for ~18% of all epileptic encephalopathies of unknown cause.</p>
      <p id="P16">The genetic heterogeneity of epileptic encephalopathies is considerable; likely pathogenic variants were found in nine known or novel genes (see <xref ref-type="fig" rid="F2">Fig. 2</xref>). Even the most commonly mutated genes in our study each account for only up to 1.6% of cases. Notably, we elucidate new genes found to be commonly mutated in epileptic encephalopathies, with <italic>CHD2, SYNGAP1</italic> and <italic>SCN2A</italic> accounting for 1â1.2% of cases each, a frequency similar to that of mutations in <italic>SCN1A</italic>, <italic>STXBP1</italic> and <italic>CDKL5</italic> in our cohort. However, no mutations were seen in nine other known genes (<italic>ARX</italic>, <italic>FOXG1, KCNT1</italic>, <italic>MECP2</italic>, <italic>PLCB1</italic>, <italic>SLC25A22</italic>, <italic>SLC2A1</italic>, <italic>SPTAN1</italic>, <italic>ARHGEF9</italic>) in 500 patients. These results suggest that pathogenic mutations in these genes, while important, are rare causes of epileptic encephalopathies (&lt;0.2% each in our cohort), or cause only very distinct syndromes that were not prevalent in our cohort. These findings support a clinical approach to genetic diagnosis that employs large gene panels or whole exome sequencing, as it will remain difficult and expensive to determine <italic>a priori</italic> the causative gene in a given patient.</p>
      <p id="P17">Notably, mutations in <italic>SYNGAP1</italic> and <italic>CHD2</italic> have now been described in probands with epileptic encephalopathy, ID and ASD phenotypes, highlighting the shared genetic basis of neurodevelopmental disorders. Unbiased approaches such as exome or whole genome sequencing provide an avenue to gene discovery, but large cohorts will be required to identify two or more patients with <italic>de novo</italic> mutations in the same gene<sup><xref rid="R9" ref-type="bibr">9</xref>, <xref rid="R18" ref-type="bibr">18</xref></sup>. Our results show the power of targeted resequencing to screen large numbers of patients in a high-throughput and cost-effective manner. This approach is critical to identify additional patients with mutations in genes where a single <italic>de novo</italic> mutation is identified by exome sequencing approaches, to determine overall mutation frequency in a given phenotype, and to describe genotype-phenotype correlations. Applying this approach across various neurodevelopmental disorders will identify additional mutation positive patients for a specific gene and enhance our understanding of disease mechanisms.</p>
    </sec>
    <sec sec-type="methods" id="S2">
      <title>ONLINE METHODS</title>
      <sec id="S3" sec-type="subjects">
        <title>Patients</title>
        <p id="P18">This study was approved by the Human Research Ethics Committees of Austin Health and the University of Washington. Probands with epileptic encephalopathies were recruited from the epilepsy clinic at Austin Health, the practices of the investigators and by referral for epilepsy genetics research from around Australia and internationally after informed consent. The cohort consisted of 500 patients with a diverse range of epileptic encephalopathy phenotypes. An epileptic encephalopathy was defined as refractory seizures and cognitive slowing or regression associated with frequent, ongoing epileptiform activity<sup><xref rid="R1" ref-type="bibr">1</xref></sup>. Detailed epilepsy and medical histories were obtained together with the results of investigations including EEG and MRI studies. Epilepsy syndromes were classified according to the Organization of the International League Against Epilepsy Commission on Classification<sup><xref rid="R1" ref-type="bibr">1</xref></sup> (<xref ref-type="table" rid="T1">Table 1</xref>). Some patients had already undergone mutation screening for specific epileptic encephalopathy genes; none had been screened for all known genes. Patients with a previously identified disease causing mutation were excluded from this study. Some patients with known mutations were included as mutation positive controls but were not included in the 500 cases in the discovery cohort. Furthermore, 369/500 patients had been previously screened for pathogenic CNVs, either in the research setting (n=257)<sup><xref rid="R3" ref-type="bibr">3</xref></sup>, or by clinical testing (n=112). Probands with pathogenic CNVs were not included in this study.</p>
      </sec>
      <sec id="S4">
        <title>Gene Selection</title>
        <p id="P19">We selected 65 genes for sequence analysis (<xref ref-type="fig" rid="F1">Fig. 1</xref>). The âknownâ gene group included genes in which mutations are known to cause one or more epileptic encephalopathy syndromes (n=19)<sup><xref rid="R2" ref-type="bibr">2</xref>, <xref rid="R21" ref-type="bibr">21</xref>, <xref rid="R25" ref-type="bibr">25</xref>, <xref rid="R27" ref-type="bibr">27</xref>, <xref rid="R28" ref-type="bibr">28</xref>, <xref rid="R32" ref-type="bibr">32</xref>â<xref rid="R34" ref-type="bibr">34</xref></sup>. We also selected two sets of candidate genes for epileptic encephalopathies. The first set includes 13 âepilepsy-associated genesâ, more commonly implicated in patients with non-epileptic encephalopathy forms of epilepsy (<italic>CHRNA7, KCNQ3, GABRD, GABRG2, PRICKLE1, CACNB4, SCN1B</italic>) or a related neurodevelopmental disorder with epilepsy as a comorbid feature (<italic>GRIN2B, MBD5, MEF2C, SYNGAP1, SYN1, ATP1A2</italic>)<sup><xref rid="R35" ref-type="bibr">35</xref>â<xref rid="R39" ref-type="bibr">39</xref></sup>. None are an established cause of epileptic encephalopathies. We also selected 33 candidate genes, primarily from epilepsy-associated CNVs, either from published cohorts, case reports or unpublished data<sup><xref rid="R3" ref-type="bibr">3</xref>, <xref rid="R4" ref-type="bibr">4</xref>, <xref rid="R40" ref-type="bibr">40</xref></sup> (see <xref ref-type="supplementary-material" rid="SD1">Supplementary Note and Supplementary Table 2</xref> for candidate gene selection).</p>
      </sec>
      <sec id="S5">
        <title>Controls</title>
        <p id="P20">Sixteen samples that had been previously subject to exome sequencing were included in all analyses and used to assess the sensitivity of variant calling. We also included 24 probands with a known variant in a known or candidate gene to further validate our approach.</p>
      </sec>
      <sec id="S6">
        <title>Target capture and sequencing</title>
        <p id="P21">We used Molecular Inversion Probes (MIPs) to capture all exon and intron/exon boundaries (5bp flanking) of target genes (Refseq, hg19 build) (<xref ref-type="supplementary-material" rid="SD1">Supplementary Table 3</xref>). Detailed methodology is described elsewhere<sup><xref rid="R11" ref-type="bibr">11</xref></sup>. Briefly, pooled MIPs were used to capture target exons from 100ng of each probandâs DNA. PCR was performed using universal primers with the introduction of unique eight-base barcodes on the tagged reverse primer. Pooled libraries were subject to massively parallel sequencing using a 101 paired-end protocol on a Hiseq. The libraries were prepared and sequenced in two batches, comprising a total of 30 (target 1) and 35 (target 2) genes.</p>
      </sec>
      <sec id="S7">
        <title>Data analysis and variant calling</title>
        <p id="P22">Raw read data processing and mapping with BWA (See URLs) was performed as described<sup><xref rid="R11" ref-type="bibr">11</xref></sup>. Single nucleotide variant (SNV) and indel calling and filtering was performed using the Genome Analysis Tool Kit (GATK) (see URLs). Variants that did not adhere to the following criteria were excluded from further analysis: allele balance &gt;0.70, QUAL&lt;30, QD&lt;5, coverage&lt;25X, clustered variants (window size-10). Variants were annotated with Seattle seq (see URLS) and the ESP6500 dataset (see URLs) was used to assess variant frequency in the control population. For dominant (or <italic>de novo</italic>) models we considered only variants not present in this control sample set. For recessive candidates, we considered variants with a frequency in controls of &lt;1%. Only non-synonymous, splice-site or frameshift (âdamagingâ) variants were assessed further. The GATK Depth of Coverage tool was used to calculate overall depth of coverage for each sample at a threshold of 25X, as well as the mean percentage (across all samples) of bases covered &gt;25X for each gene.</p>
      </sec>
      <sec id="S8">
        <title>Rare variant segregation analysis</title>
        <p id="P23">Where family members were available, segregation analysis was carried out for all rare (not present in ESP6500 controls), possibly damaging (non-synonymous, essential splice-site or frameshift) variants for all 65 target genes. This analysis was performed using a âMIP-pickâ strategy. We selected and re-pooled only the MIPs that captured the genomic sequence harboring the rare variant of interest and performed target enrichment PCR and sequencing as above for all relevant probands and family members. This approach allowed us to sequence variants at very high depth and detect somatic mosaicism in parents.</p>
      </sec>
      <sec id="S9">
        <title>Criteria for pathogenicity of rare variants</title>
        <p id="P24">For those rare, possibly damaging variants where segregation analysis could be performed, we required the variant to meet one of the following criteria to constitute a novel pathogenic variant. Pathogenic variants: (i) arose <italic>de novo,</italic> (ii) segregated with the disorder, (iii) were inherited from a parent with somatic mosaicism, or (iv) adhered to a recessive, X-linked or parent-of-origin mode of inheritance, where applicable (<xref ref-type="supplementary-material" rid="SD1">Supplementary Fig. 1</xref>).</p>
        <p id="P25">In certain instances we were unable to determine the inheritance of a rare variant due to the unavailability of DNA from one or more parent. It is likely that a subset of these variants also cause disease, though here we report only those variants that are likely to lead to protein truncation (i.e. splice-site, nonsense, frameshift, stop-loss) as being âlikely pathogenicâ. Additionally, two missense mutations in known genes (<italic>STXBP1, SCN2A</italic>) were interpreted to be âlikely pathogenicâ based on the high incidence of pathogenic missense mutations in these genes, which was further supported by the available parent not carrying the variant. We performed microsatellite analysis using the PowerPlex S5 system [Promega] in all parents of probands with a <italic>de novo</italic> mutation to confirm maternity and paternity.</p>
      </sec>
    </sec>
    <sec sec-type="supplementary-material" id="SM">
      <title>Supplementary Material</title>
      <supplementary-material content-type="local-data" id="SD1">
        <label>1</label>
        <media xlink:href="NIHMS474984-supplement-1.pdf" mimetype="application" mime-subtype="pdf" orientation="portrait" xlink:type="simple" id="d37e1044" position="anchor"/>
      </supplementary-material>
    </sec>
  </body>
  <back>
    <ack id="S10">
      <title>Acknowledgements</title>
      <p id="P26">We thank the patients and their families for participating in our research. H.C.M. is supported by a grant from the NIH (NINDS 1R01NS069605) and is a recipient of a Burroughs Wellcome Fund Career Award for Medical Scientists. This work was supported by the National Health and Medical Research Council of Australia (Program Grant 628952 to S.F.B., I.E.S., Practitioner Fellowship 1006110 to I.E.S and the Health Research Council of New Zealand project grant to L.G.S.)</p>
    </ack>
    <fn-group>
      <fn id="FN1" fn-type="con">
        <p id="P27">
          <bold>Author contribution statement</bold>
        </p>
        <p id="P28">GLC, HCM and IES designed the study and wrote the manuscript. HCM and IES supervised the study. GLC constructed libraries, developed the variant calling pipeline (assisted by JC), and analyzed the sequence data. BJO and JS developed the MIPs methodology and analysis pipeline. SBH, SCY, JMM, SC, SM, GW, TS, AMEB, AB, KBH, SK, MTM, VRC, RW, AK, ZA, NZ, TLS, DL, RSM, DG, DMA, JLF, LGS, SFB, IES performed phenotypic analysis. SBH, JMM, SFB and IES critically reviewed the manuscript. GLC and AK performed segregation analysis experiments. MOD and MW performed Illumina Hiseq sequencing.</p>
      </fn>
      <fn id="FN2">
        <p id="P29">
          <bold>Resources</bold>
        </p>
        <p id="P30">Exome Variant Server, NHLBI GO Exome Sequencing Project (ESP), Seattle, WA (URL: <ext-link ext-link-type="uri" xlink:href="http://evs.gs.washington.edu/EVS/">http://evs.gs.washington.edu/EVS/</ext-link>) [10/2012 accessed]</p>
        <p id="P31">Genome Analysis Toolkit GATK (version 2.2) (<ext-link ext-link-type="uri" xlink:href="http://www.broadinstitute.org/gatk/">http://www.broadinstitute.org/gatk/</ext-link>)</p>
        <p id="P32">Seattle seq (version 134) (<ext-link ext-link-type="uri" xlink:href="http://snp.gs.washington.edu/SeattleSeqAnnotation134/">http://snp.gs.washington.edu/SeattleSeqAnnotation134/</ext-link>)</p>
        <p id="P33">BWA; Burrows-Wheeler Aligner (version 0.5.9) (<ext-link ext-link-type="uri" xlink:href="http://bio-bwa.sourceforge.net/">http://bio-bwa.sourceforge.net/</ext-link>)</p>
        <p id="P34">Picard tools (version 1.82) (<ext-link ext-link-type="uri" xlink:href="http://picard.sourceforge.net/">http://picard.sourceforge.net/</ext-link>)</p>
        <p id="P35">Polyphen2 (URL: <ext-link ext-link-type="uri" xlink:href="http://genetics.bwh.harvard.edu/pph2/">http://genetics.bwh.harvard.edu/pph2/</ext-link>)</p>
        <p id="P36">SIFT, Sorting Intolerant from Tolerant, (URL: <ext-link ext-link-type="uri" xlink:href="http://sift.bii.a-star.edu.sg/">http://sift.bii.a-star.edu.sg/</ext-link>)</p>
      </fn>
    </fn-group>
    <ref-list>
      <title>References</title>
      <ref id="R1">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Berg</surname>
              <given-names>AT</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology 2005â2009</article-title>
          <source>Epilepsia</source>
          <year>2010</year>
          <volume>51</volume>
          <fpage>676</fpage>
          <lpage>685</lpage>
          <pub-id pub-id-type="pmid">20196795</pub-id>
        </element-citation>
      </ref>
      <ref id="R2">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kamien</surname>
              <given-names>BA</given-names>
            </name>
            <name>
              <surname>Cardamone</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Lawson</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Sachdev</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>A genetic diagnostic approach to infantile epileptic encephalopathies</article-title>
          <source>J. Clin. Neurosci</source>
          <year>2012</year>
          <volume>19</volume>
          <fpage>934</fpage>
          <lpage>941</lpage>
          <pub-id pub-id-type="pmid">22617547</pub-id>
        </element-citation>
      </ref>
      <ref id="R3">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mefford</surname>
              <given-names>HC</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Rare copy number variants are an important cause of epileptic encephalopathies</article-title>
          <source>Ann. Neurol</source>
          <year>2011</year>
          <volume>70</volume>
          <fpage>974</fpage>
          <lpage>985</lpage>
          <pub-id pub-id-type="pmid">22190369</pub-id>
        </element-citation>
      </ref>
      <ref id="R4">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Heinzen</surname>
              <given-names>EL</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Rare deletions at 16p13.11 predispose to a diverse spectrum of sporadic epilepsy syndromes</article-title>
          <source>Am. J Hum. Genet</source>
          <year>2010</year>
          <volume>86</volume>
          <fpage>707</fpage>
          <lpage>718</lpage>
          <pub-id pub-id-type="pmid">20398883</pub-id>
        </element-citation>
      </ref>
      <ref id="R5">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Capelli</surname>
              <given-names>LP</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Deletion of the RMGA and CHD2 genes in a child with epilepsy and mental deficiency</article-title>
          <source>Eur. J. Med. Genet</source>
          <year>2012</year>
          <volume>55</volume>
          <fpage>132</fpage>
          <lpage>134</lpage>
          <pub-id pub-id-type="pmid">22178256</pub-id>
        </element-citation>
      </ref>
      <ref id="R6">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dhamija</surname>
              <given-names>R</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Microdeletion of chromosome 15q26.1 in a child with intractable generalized epilepsy</article-title>
          <source>Pediatr. Neurol</source>
          <year>2011</year>
          <volume>45</volume>
          <fpage>60</fpage>
          <lpage>62</lpage>
          <pub-id pub-id-type="pmid">21723464</pub-id>
        </element-citation>
      </ref>
      <ref id="R7">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Marfella</surname>
              <given-names>CG</given-names>
            </name>
            <name>
              <surname>Imbalzano</surname>
              <given-names>AN</given-names>
            </name>
          </person-group>
          <article-title>The Chd family of chromatin remodelers</article-title>
          <source>Mutat. Res</source>
          <year>2007</year>
          <volume>618</volume>
          <fpage>30</fpage>
          <lpage>40</lpage>
          <pub-id pub-id-type="pmid">17350655</pub-id>
        </element-citation>
      </ref>
      <ref id="R8">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bouazoune</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Kingston</surname>
              <given-names>RE</given-names>
            </name>
          </person-group>
          <article-title>Chromatin remodeling by the CHD7 protein is impaired by mutations that cause human developmental disorders</article-title>
          <source>Proc. Natl. Acad. Sci. U.S.A</source>
          <year>2012</year>
          <volume>109</volume>
          <fpage>19238</fpage>
          <lpage>19243</lpage>
          <pub-id pub-id-type="pmid">23134727</pub-id>
        </element-citation>
      </ref>
      <ref id="R9">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rauch</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Range of genetic mutations associated with severe non-syndromic sporadic intellectual disability: an exome sequencing study</article-title>
          <source>Lancet</source>
          <year>2012</year>
        </element-citation>
      </ref>
      <ref id="R10">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Neale</surname>
              <given-names>BM</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Patterns and rates of exonic de novo mutations in autism spectrum disorders</article-title>
          <source>Nature</source>
          <year>2012</year>
          <volume>485</volume>
          <fpage>242</fpage>
          <lpage>245</lpage>
          <pub-id pub-id-type="pmid">22495311</pub-id>
        </element-citation>
      </ref>
      <ref id="R11">
        <label>11</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>O'Roak</surname>
              <given-names>BJ</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Multiplex Targeted Sequencing Identifies Recurrently Mutated Genes in Autism Spectrum Disorders</article-title>
          <year>2012</year>
          <comment>Published online November 15, 2012</comment>
        </element-citation>
      </ref>
      <ref id="R12">
        <label>12</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hamdan</surname>
              <given-names>FF</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Mutations in SYNGAP1 in autosomal nonsyndromic mental retardation</article-title>
          <source>N. Engl. J. Med</source>
          <year>2009</year>
          <volume>360</volume>
          <fpage>599</fpage>
          <lpage>605</lpage>
          <pub-id pub-id-type="pmid">19196676</pub-id>
        </element-citation>
      </ref>
      <ref id="R13">
        <label>13</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hamdan</surname>
              <given-names>FF</given-names>
            </name>
            <name>
              <surname>Gauthier</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Rouleau</surname>
              <given-names>GA</given-names>
            </name>
            <name>
              <surname>Michaud</surname>
              <given-names>JL</given-names>
            </name>
          </person-group>
          <article-title>De novo mutations in SYNGAP1 associated with non-syndromic mental retardation</article-title>
          <source>Med. Sci. (Paris)</source>
          <year>2010</year>
          <volume>26</volume>
          <fpage>133</fpage>
          <lpage>135</lpage>
          <pub-id pub-id-type="pmid">20188038</pub-id>
        </element-citation>
      </ref>
      <ref id="R14">
        <label>14</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hamdan</surname>
              <given-names>FF</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>De novo SYNGAP1 mutations in nonsyndromic intellectual disability and autism</article-title>
          <source>Biol. Psychiatry</source>
          <year>2011</year>
          <volume>69</volume>
          <fpage>898</fpage>
          <lpage>901</lpage>
          <pub-id pub-id-type="pmid">21237447</pub-id>
        </element-citation>
      </ref>
      <ref id="R15">
        <label>15</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hamdan</surname>
              <given-names>FF</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Excess of de novo deleterious mutations in genes associated with glutamatergic systems in nonsyndromic intellectual disability</article-title>
          <source>Am. J. Hum. Genet</source>
          <year>2011</year>
          <volume>88</volume>
          <fpage>306</fpage>
          <lpage>316</lpage>
          <pub-id pub-id-type="pmid">21376300</pub-id>
        </element-citation>
      </ref>
      <ref id="R16">
        <label>16</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Berryer</surname>
              <given-names>MH</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Mutations in SYNGAP1 Cause Intellectual Disability, Autism and a Specific form of Epilepsy by Inducing Haploinsufficiency</article-title>
          <source>Hum. Mutat</source>
          <year>2012</year>
        </element-citation>
      </ref>
      <ref id="R17">
        <label>17</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vissers</surname>
              <given-names>LE</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>A de novo paradigm for mental retardation</article-title>
          <source>Nat. Genet</source>
          <year>2010</year>
          <volume>42</volume>
          <fpage>1109</fpage>
          <lpage>1112</lpage>
          <pub-id pub-id-type="pmid">21076407</pub-id>
        </element-citation>
      </ref>
      <ref id="R18">
        <label>18</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>de Ligt</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Diagnostic Exome Sequencing in Persons with Severe Intellectual Disability</article-title>
          <source>N. Engl. Med</source>
          <year>2012</year>
        </element-citation>
      </ref>
      <ref id="R19">
        <label>19</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Thierry</surname>
              <given-names>G</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Molecular characterization of 1q44 microdeletion in 11 patients reveals three candidate genes for intellectual disability and seizures</article-title>
          <source>Am. J. Med. Genet. A</source>
          <year>2012</year>
          <volume>158A</volume>
          <fpage>1633</fpage>
          <lpage>1640</lpage>
          <pub-id pub-id-type="pmid">22678713</pub-id>
        </element-citation>
      </ref>
      <ref id="R20">
        <label>20</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Need</surname>
              <given-names>AC</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Clinical application of exome sequencing in undiagnosed genetic conditions</article-title>
          <source>J. Med. Genet</source>
          <year>2012</year>
          <volume>49</volume>
          <fpage>353</fpage>
          <lpage>361</lpage>
          <pub-id pub-id-type="pmid">22581936</pub-id>
        </element-citation>
      </ref>
      <ref id="R21">
        <label>21</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shen</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Mutations in PNKP cause microcephaly, seizures and defects in DNA repair</article-title>
          <source>Nat. Genet</source>
          <year>2010</year>
          <volume>42</volume>
          <fpage>245</fpage>
          <lpage>249</lpage>
          <pub-id pub-id-type="pmid">20118933</pub-id>
        </element-citation>
      </ref>
      <ref id="R22">
        <label>22</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tsai</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Clinical genetic study of the epilepsy-aphasia spectrum</article-title>
          <source>Epilepsia</source>
          <year>2012</year>
          <date-in-citation>Accepted 30 October</date-in-citation>
        </element-citation>
      </ref>
      <ref id="R23">
        <label>23</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Escayg</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Mutations of SCN1A, encoding a neuronal sodium channel, in two families with GEFS+2</article-title>
          <source>Nat Genet</source>
          <year>2000</year>
          <volume>24</volume>
          <fpage>343</fpage>
          <lpage>345</lpage>
          <pub-id pub-id-type="pmid">10742094</pub-id>
        </element-citation>
      </ref>
      <ref id="R24">
        <label>24</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Oliva</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Berkovic</surname>
              <given-names>SF</given-names>
            </name>
            <name>
              <surname>Petrou</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Sodium channels and the neurobiology of epilepsy</article-title>
          <source>Epilepsia</source>
          <year>2012</year>
          <volume>53</volume>
          <fpage>1849</fpage>
          <lpage>1859</lpage>
          <pub-id pub-id-type="pmid">22905747</pub-id>
        </element-citation>
      </ref>
      <ref id="R25">
        <label>25</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ogiwara</surname>
              <given-names>I</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>De novo mutations of voltage-gated sodium channel alphaII gene SCN2A in intractable epilepsies</article-title>
          <source>Neurology</source>
          <year>2009</year>
          <volume>73</volume>
          <fpage>1046</fpage>
          <lpage>1053</lpage>
          <pub-id pub-id-type="pmid">19786696</pub-id>
        </element-citation>
      </ref>
      <ref id="R26">
        <label>26</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kamiya</surname>
              <given-names>K</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>A nonsense mutation of the sodium channel gene SCN2A in a patient with intractable epilepsy and mental decline</article-title>
          <source>J. Neurosci</source>
          <year>2004</year>
          <volume>24</volume>
          <fpage>2690</fpage>
          <lpage>2698</lpage>
          <pub-id pub-id-type="pmid">15028761</pub-id>
        </element-citation>
      </ref>
      <ref id="R27">
        <label>27</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Veeramah</surname>
              <given-names>KR</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>De novo pathogenic SCN8A mutation identified by whole-genome sequencing of a family quartet affected by infantile epileptic encephalopathy and SUDEP</article-title>
          <source>Am. J. Hum. Genet</source>
          <year>2012</year>
          <volume>90</volume>
          <fpage>502</fpage>
          <lpage>510</lpage>
          <pub-id pub-id-type="pmid">22365152</pub-id>
        </element-citation>
      </ref>
      <ref id="R28">
        <label>28</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Weckhuysen</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>KCNQ2 encephalopathy: emerging phenotype of a neonatal epileptic encephalopathy</article-title>
          <source>Ann. Neurol</source>
          <year>2012</year>
          <volume>71</volume>
          <fpage>15</fpage>
          <lpage>25</lpage>
          <pub-id pub-id-type="pmid">22275249</pub-id>
        </element-citation>
      </ref>
      <ref id="R29">
        <label>29</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fujiwara</surname>
              <given-names>T</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Mutations of sodium channel alpha subunit type 1 (SCN1A) in intractable childhood epilepsies with frequent generalized tonic-clonic seizures</article-title>
          <source>Brain</source>
          <year>2003</year>
          <volume>126</volume>
          <fpage>531</fpage>
          <lpage>546</lpage>
          <pub-id pub-id-type="pmid">12566275</pub-id>
        </element-citation>
      </ref>
      <ref id="R30">
        <label>30</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Camprubi</surname>
              <given-names>C</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Novel UBE3A mutations causing Angelman syndrome: different parental origin for single nucleotide changes and multiple nucleotide deletions or insertions</article-title>
          <source>Am J. Med. Genet. A</source>
          <year>2009</year>
          <volume>149A</volume>
          <fpage>343</fpage>
          <lpage>348</lpage>
          <pub-id pub-id-type="pmid">19213023</pub-id>
        </element-citation>
      </ref>
      <ref id="R31">
        <label>31</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mills</surname>
              <given-names>PB</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Neonatal epileptic encephalopathy caused by mutations in the PNPO gene encoding pyridox(am)ine 5'-phosphate oxidase</article-title>
          <source>Hum. Mol. Genet</source>
          <year>2005</year>
          <volume>14</volume>
          <fpage>1077</fpage>
          <lpage>1086</lpage>
          <pub-id pub-id-type="pmid">15772097</pub-id>
        </element-citation>
      </ref>
      <ref id="R32">
        <label>32</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Heron</surname>
              <given-names>SE</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Missense mutations in the sodium-gated potassium channel gene KCNT1 cause severe autosomal dominant nocturnal frontal lobe epilepsy</article-title>
          <source>Nat. Genet</source>
          <year>2012</year>
          <volume>44</volume>
          <fpage>1188</fpage>
          <lpage>1190</lpage>
          <pub-id pub-id-type="pmid">23086396</pub-id>
        </element-citation>
      </ref>
      <ref id="R33">
        <label>33</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Marco</surname>
              <given-names>EJ</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>ARHGEF9 disruption in a female patient is associated with X linked mental retardation and sensory hyperarousal</article-title>
          <source>BMJ Case Rep</source>
          <year>2009</year>
          <volume>2009</volume>
          <comment>Epub 2009 Jul 2</comment>
        </element-citation>
      </ref>
      <ref id="R34">
        <label>34</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mastrangelo</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Leuzzi</surname>
              <given-names>V</given-names>
            </name>
          </person-group>
          <article-title>Genes of early-onset epileptic encephalopathies: from genotype to phenotype</article-title>
          <source>Pediatr. Neurol</source>
          <year>2012</year>
          <volume>46</volume>
          <fpage>24</fpage>
          <lpage>31</lpage>
          <pub-id pub-id-type="pmid">22196487</pub-id>
        </element-citation>
      </ref>
      <ref id="R35">
        <label>35</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tao</surname>
              <given-names>H</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Mutations in prickle orthologs cause seizures in flies, mice, and humans</article-title>
          <source>Am. J. Hum. Genet</source>
          <year>2011</year>
          <volume>88</volume>
          <fpage>138</fpage>
          <lpage>149</lpage>
          <pub-id pub-id-type="pmid">21276947</pub-id>
        </element-citation>
      </ref>
      <ref id="R36">
        <label>36</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Endele</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Mutations in GRIN2A and GRIN2B encoding regulatory subunits of NMDA receptors cause variable neurodevelopmental phenotypes</article-title>
          <source>Nat. Genet</source>
          <year>2010</year>
          <volume>42</volume>
          <fpage>1021</fpage>
          <lpage>1026</lpage>
          <pub-id pub-id-type="pmid">20890276</pub-id>
        </element-citation>
      </ref>
      <ref id="R37">
        <label>37</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hoppman-Chaney</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Wain</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Seger</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Superneau</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Hodge</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Identification of single gene deletions at 15q13.3: further evidence that CHRNA7 causes the 15q13.3 microdeletion syndrome phenotype</article-title>
          <source>Clin. Genet</source>
          <year>2012</year>
        </element-citation>
      </ref>
      <ref id="R38">
        <label>38</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Talkowski</surname>
              <given-names>ME</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Assessment of 2q23.1 microdeletion syndrome implicates MBD5 as a single causal locus of intellectual disability, epilepsy, and autism spectrum disorder</article-title>
          <source>Am. J. Hum. Genet</source>
          <year>2011</year>
          <volume>89</volume>
          <fpage>551</fpage>
          <lpage>563</lpage>
          <pub-id pub-id-type="pmid">21981781</pub-id>
        </element-citation>
      </ref>
      <ref id="R39">
        <label>39</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zweier</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Mutations in MEF2C from the 5q14.3q15 microdeletion syndrome region are a frequent cause of severe mental retardation and diminish MECP2 and CDKL5 expression</article-title>
          <source>Hum. Mutat</source>
          <year>2010</year>
          <volume>31</volume>
          <fpage>722</fpage>
          <lpage>733</lpage>
          <pub-id pub-id-type="pmid">20513142</pub-id>
        </element-citation>
      </ref>
      <ref id="R40">
        <label>40</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mefford</surname>
              <given-names>HC</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Genome-wide copy number variation in epilepsy: novel susceptibility loci in idiopathic generalized and focal epilepsies</article-title>
          <source>PLoS Genet</source>
          <year>2010</year>
          <volume>6</volume>
          <fpage>e1000962</fpage>
          <pub-id pub-id-type="pmid">20502679</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <floats-group>
    <fig id="F1" orientation="portrait" position="float">
      <label>Figure 1</label>
      <caption>
        <p id="P37">Pathogenic and likely pathogenic mutations identified in 500 patients with epileptic encephalopathies in novel genes (red) and known genes (blue)</p>
      </caption>
      <graphic xlink:href="nihms474984f1"/>
    </fig>
    <fig id="F2" orientation="portrait" position="float">
      <label>Figure 2</label>
      <caption>
        <p id="P38"><italic>De novo</italic> mutations in novel epileptic encephalopathy genes a) <italic>CHD2</italic> and b) <italic>SYNGAP1</italic>. Mutations shown in red were identified in this study. Black entries denote previously reported variants; for CHD2, in ID (Thr604Leufs*19)<sup><xref rid="R9" ref-type="bibr">9</xref></sup> and autism (Asp856Gly)<sup><xref rid="R10" ref-type="bibr">10</xref></sup> and for SYNGAP1 in ID and/or autism<sup><xref rid="R9" ref-type="bibr">9</xref>, <xref rid="R14" ref-type="bibr">14</xref>â<xref rid="R18" ref-type="bibr">18</xref></sup>. Bold entries indicate pathogenic variants found in patients with epilepsy. No evident genotype-phenotype correlations exist for mutations in either CHD2 or SYNGAP1. For both genes, truncating and missense mutations occur in all three phenotypes (ID/epileptic encephalopathy /autism) without phenotype-specific intragenic localization. This suggests that alternative neurobiological conditions and mechanisms, genetic or otherwise, underlie this heterogeneity.</p>
      </caption>
      <graphic xlink:href="nihms474984f2"/>
    </fig>
    <table-wrap id="T1" position="float" orientation="portrait">
      <label>Table 1</label>
      <caption>
        <p id="P39">Epileptic encephalopathy cohort screened for mutations in 65 novel and known genes</p>
      </caption>
      <table frame="box" rules="all">
        <thead>
          <tr>
            <th align="left" valign="top" rowspan="1" colspan="1">Syndrome</th>
            <th align="center" valign="top" rowspan="1" colspan="1">N</th>
            <th align="center" rowspan="1" colspan="1">Pathogenic or likely<break/>pathogenic variant<break/>(% of syndrome)</th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td align="left" rowspan="1" colspan="1">ABPE</td>
            <td align="center" rowspan="1" colspan="1">6</td>
            <td align="center" rowspan="1" colspan="1">0</td>
          </tr>
          <tr>
            <td align="left" rowspan="1" colspan="1">Dravet</td>
            <td align="center" rowspan="1" colspan="1">19</td>
            <td align="center" rowspan="1" colspan="1">4 (21%)<xref ref-type="table-fn" rid="TFN2">â </xref></td>
          </tr>
          <tr>
            <td align="left" rowspan="1" colspan="1">ECSWS</td>
            <td align="center" rowspan="1" colspan="1">10</td>
            <td align="center" rowspan="1" colspan="1">0</td>
          </tr>
          <tr>
            <td align="left" rowspan="1" colspan="1">Epileptic encephalopathy not otherwise specified</td>
            <td align="center" rowspan="1" colspan="1">173</td>
            <td align="center" rowspan="1" colspan="1">22 (13%)</td>
          </tr>
          <tr>
            <td align="left" rowspan="1" colspan="1">EME</td>
            <td align="center" rowspan="1" colspan="1">5</td>
            <td align="center" rowspan="1" colspan="1">1 (20%)</td>
          </tr>
          <tr>
            <td align="left" rowspan="1" colspan="1">EOEE</td>
            <td align="center" rowspan="1" colspan="1">39</td>
            <td align="center" rowspan="1" colspan="1">8(21%)</td>
          </tr>
          <tr>
            <td align="left" rowspan="1" colspan="1">Epilepsy-Aphasia</td>
            <td align="center" rowspan="1" colspan="1">27</td>
            <td align="center" rowspan="1" colspan="1">3 (11%)</td>
          </tr>
          <tr>
            <td align="left" rowspan="1" colspan="1">FIRES</td>
            <td align="center" rowspan="1" colspan="1">12</td>
            <td align="center" rowspan="1" colspan="1">0</td>
          </tr>
          <tr>
            <td align="left" rowspan="1" colspan="1">IS</td>
            <td align="center" rowspan="1" colspan="1">81</td>
            <td align="center" rowspan="1" colspan="1">4(5%)</td>
          </tr>
          <tr>
            <td align="left" rowspan="1" colspan="1">LKS</td>
            <td align="center" rowspan="1" colspan="1">3</td>
            <td align="center" rowspan="1" colspan="1">0</td>
          </tr>
          <tr>
            <td align="left" rowspan="1" colspan="1">LGS</td>
            <td align="center" rowspan="1" colspan="1">40</td>
            <td align="center" rowspan="1" colspan="1">5 (13%)</td>
          </tr>
          <tr>
            <td align="left" rowspan="1" colspan="1">MAE</td>
            <td align="center" rowspan="1" colspan="1">81</td>
            <td align="center" rowspan="1" colspan="1">3 (4%)</td>
          </tr>
          <tr>
            <td align="left" rowspan="1" colspan="1">Ohtahara</td>
            <td align="center" rowspan="1" colspan="1">4</td>
            <td align="center" rowspan="1" colspan="1">2 (50%)</td>
          </tr>
          <tr>
            <td align="left" rowspan="1" colspan="1">
              <bold>TOTAL</bold>
            </td>
            <td align="center" rowspan="1" colspan="1">
              <bold>500</bold>
            </td>
            <td align="center" rowspan="1" colspan="1">
              <bold>52 (10%)</bold>
            </td>
          </tr>
        </tbody>
      </table>
      <table-wrap-foot>
        <fn id="TFN1">
          <p id="P40">ABPE = Atypical Benign Partial Epilepsy; ECSWS, = Epileptic encephalopathy with Continuous Spike-and-Wave during Sleep; EME = Early Myoclonic Encephalopathy, EOEE = Early Onset Epileptic Encephalopathy; FIRES = Febrile Infection-Related Epilepsy Syndrome; IS = Infantile Spasms; LKS = Landau-Kleffner Syndrome; LGS = Lennox-Gastaut Syndrome; MAE = Myoclonic Atonic Epilepsy</p>
        </fn>
        <fn id="TFN2">
          <label>â </label>
          <p id="P41">Note that in 4 of the Dravet syndrome cases included here, <italic>SCN1A</italic> testing had not yet been undertaken.</p>
        </fn>
      </table-wrap-foot>
    </table-wrap>
    <table-wrap id="T2" position="float" orientation="landscape">
      <label>Table 2</label>
      <caption>
        <p id="P42">Pathogenic and likely pathogenic variants in novel epileptic encephalopathy genes</p>
      </caption>
      <table frame="box" rules="rows">
        <thead>
          <tr>
            <th align="left" rowspan="1" colspan="1">Proband<break/>(gender, study age)</th>
            <th align="left" valign="top" rowspan="1" colspan="1">Gene</th>
            <th align="left" rowspan="1" colspan="1">Protein change<break/>(Polyphen, SIFT)<xref ref-type="table-fn" rid="TFN3">&amp;</xref></th>
            <th align="left" valign="top" rowspan="1" colspan="1">Diagnosis</th>
            <th align="left" valign="top" rowspan="1" colspan="1">Seizures<xref ref-type="table-fn" rid="TFN4">$</xref> (age of onset)</th>
            <th align="left" valign="top" rowspan="1" colspan="1">EEG</th>
            <th align="left" rowspan="1" colspan="1">Development prior to <break/>seizure onset</th>
            <th align="left" rowspan="1" colspan="1">Cognitive outcome<break/>(regression)</th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td align="left" colspan="3" rowspan="1">
              <bold>Pathogenic variants (<italic>de novo</italic>)</bold>
            </td>
            <td align="left" rowspan="1" colspan="1"/>
            <td align="left" rowspan="1" colspan="1"/>
            <td align="left" rowspan="1" colspan="1"/>
            <td align="left" rowspan="1" colspan="1"/>
            <td align="left" rowspan="1" colspan="1"/>
          </tr>
          <tr>
            <td align="left" rowspan="1" colspan="1">T38 (M, 17 yr)</td>
            <td align="left" rowspan="1" colspan="1">
              <italic>CHD2</italic>
            </td>
            <td align="left" rowspan="1" colspan="1">Glu1412Glyfs*64</td>
            <td align="left" rowspan="1" colspan="1">MAE</td>
            <td align="left" rowspan="1" colspan="1">At (12mth) FS, Ab, MJ-At, MJ, TC</td>
            <td align="left" rowspan="1" colspan="1">3.8 Hz GSW</td>
            <td align="left" rowspan="1" colspan="1">mild delay, behavioral problems</td>
            <td align="left" rowspan="1" colspan="1">moderate ID, ASD (no)</td>
          </tr>
          <tr>
            <td align="left" rowspan="1" colspan="1">T18697 (F, 12 yr)</td>
            <td align="left" rowspan="1" colspan="1">
              <italic>CHD2</italic>
            </td>
            <td align="left" rowspan="1" colspan="1">Arg121*</td>
            <td align="left" rowspan="1" colspan="1">EE</td>
            <td align="left" rowspan="1" colspan="1">MJ(12mth) NCS, T, TC, MAb</td>
            <td align="left" rowspan="1" colspan="1">GPSW, MFD, GPFA, SSW</td>
            <td align="left" rowspan="1" colspan="1">Normal</td>
            <td align="left" rowspan="1" colspan="1">severe ID (yes)</td>
          </tr>
          <tr>
            <td align="left" rowspan="1" colspan="1">T2608 (F, 29 yr)</td>
            <td align="left" rowspan="1" colspan="1">
              <italic>CHD2</italic>
            </td>
            <td align="left" rowspan="1" colspan="1">Gly491Valfs*13</td>
            <td align="left" rowspan="1" colspan="1">LGS</td>
            <td align="left" rowspan="1" colspan="1">aAb (12mth) At, MJ, NCS, SE, T, TC</td>
            <td align="left" rowspan="1" colspan="1">SSW, MFD, DS, GPSW, PPR triggered MJ</td>
            <td align="left" rowspan="1" colspan="1">Delayed</td>
            <td align="left" rowspan="1" colspan="1">severe ID (yes)</td>
          </tr>
          <tr>
            <td align="left" rowspan="1" colspan="1">T20240 (M, 12 yr)</td>
            <td align="left" rowspan="1" colspan="1">
              <italic>CHD2</italic>
            </td>
            <td align="left" rowspan="1" colspan="1">Arg1644Lysfs*22</td>
            <td align="left" rowspan="1" colspan="1">MAE</td>
            <td align="left" rowspan="1" colspan="1">At (2y) MJ, SE, TC</td>
            <td align="left" rowspan="1" colspan="1">DS, GPSW, 2.5 Hz GSW</td>
            <td align="left" rowspan="1" colspan="1">Normal</td>
            <td align="left" rowspan="1" colspan="1">severe ID (yes) T17756</td>
          </tr>
          <tr>
            <td align="left" rowspan="1" colspan="1">T17756 (M, 15 yr)</td>
            <td align="left" rowspan="1" colspan="1">
              <italic>CHD2</italic>
            </td>
            <td align="left" rowspan="1" colspan="1">Trp548Arg (1, 0)</td>
            <td align="left" rowspan="1" colspan="1">EE</td>
            <td align="left" rowspan="1" colspan="1">TC (3y) FDS, H, MJ</td>
            <td align="left" rowspan="1" colspan="1">GSW, MFD, DS</td>
            <td align="left" rowspan="1" colspan="1">Delayed</td>
            <td align="left" rowspan="1" colspan="1">Moderate ID (yes)</td>
          </tr>
          <tr>
            <td align="left" rowspan="1" colspan="1">T18431 (M, 2.5 yr)</td>
            <td align="left" rowspan="1" colspan="1">
              <italic>CHD2</italic>
            </td>
            <td align="left" rowspan="1" colspan="1">Leu823Pro (0.999, 0)</td>
            <td align="left" rowspan="1" colspan="1">EE</td>
            <td align="left" rowspan="1" colspan="1">FDS, MJ (2.5y) MJ-Ab, T</td>
            <td align="left" rowspan="1" colspan="1">GSW, GPSW, MFD</td>
            <td align="left" rowspan="1" colspan="1">Delayed</td>
            <td align="left" rowspan="1" colspan="1">Severe ID, ASD (yes)</td>
          </tr>
          <tr>
            <td align="left" rowspan="1" colspan="1">T15923 (F, 26 yr)</td>
            <td align="left" rowspan="1" colspan="1">
              <italic>SYNGAP1</italic>
            </td>
            <td align="left" rowspan="1" colspan="1">Trp267*</td>
            <td align="left" rowspan="1" colspan="1">EE</td>
            <td align="left" rowspan="1" colspan="1">aAb(3y) At, Aura, FDS, MJ</td>
            <td align="left" rowspan="1" colspan="1">SSW, MFD</td>
            <td align="left" rowspan="1" colspan="1">Delayed</td>
            <td align="left" rowspan="1" colspan="1">Severe ID, ASD (yes)</td>
          </tr>
          <tr>
            <td align="left" rowspan="1" colspan="1">T2528 (M, 26 yr)</td>
            <td align="left" rowspan="1" colspan="1">
              <italic>SYNGAP1</italic>
            </td>
            <td align="left" rowspan="1" colspan="1">Gln702*</td>
            <td align="left" rowspan="1" colspan="1">EE</td>
            <td align="left" rowspan="1" colspan="1">FS (18mth) Ab, Aura, FDS, MJ, NCS, TC</td>
            <td align="left" rowspan="1" colspan="1">SSW, bi-occipital ED, DS</td>
            <td align="left" rowspan="1" colspan="1">Delayed</td>
            <td align="left" rowspan="1" colspan="1">Moderate ID (yes)</td>
          </tr>
          <tr>
            <td align="left" rowspan="1" colspan="1">T1898 (F, 20 yr)</td>
            <td align="left" rowspan="1" colspan="1">
              <italic>MBD5</italic>
            </td>
            <td align="left" rowspan="1" colspan="1">Thr157Glnfs*4</td>
            <td align="left" rowspan="1" colspan="1">EE</td>
            <td align="left" rowspan="1" colspan="1">TC (6mth) Ab, FDS, Focal,,T</td>
            <td align="left" rowspan="1" colspan="1">GPSW, MFD, DS</td>
            <td align="left" rowspan="1" colspan="1">Delayed</td>
            <td align="left" rowspan="1" colspan="1">Severe ID, ASD (no)</td>
          </tr>
          <tr>
            <td align="left" rowspan="1" colspan="1">T20719 (M, 2.5 yr)</td>
            <td align="left" rowspan="1" colspan="1">
              <italic>GABRG2</italic>
            </td>
            <td align="left" rowspan="1" colspan="1">Arg323Gln (0.998,0)</td>
            <td align="left" rowspan="1" colspan="1">MAE</td>
            <td align="left" rowspan="1" colspan="1">FS (8mth) Ab. At, MJ, TC</td>
            <td align="left" rowspan="1" colspan="1">Normal</td>
            <td align="left" rowspan="1" colspan="1">Normal</td>
            <td align="left" rowspan="1" colspan="1">Normal (yes)</td>
          </tr>
          <tr>
            <td align="left" rowspan="1" colspan="1">T23549 (F, 3.5 yr)</td>
            <td align="left" rowspan="1" colspan="1">
              <italic>MEF2C</italic>
            </td>
            <td align="left" rowspan="1" colspan="1">Cys39Arg (0.998, 0)</td>
            <td align="left" rowspan="1" colspan="1">EE</td>
            <td align="left" rowspan="1" colspan="1">FS (13mth) Ab, SE, TC</td>
            <td align="left" rowspan="1" colspan="1">MFD, DS</td>
            <td align="left" rowspan="1" colspan="1">Delayed</td>
            <td align="left" rowspan="1" colspan="1">Severe ID, ASD (yes)</td>
          </tr>
          <tr>
            <td align="left" rowspan="1" colspan="1">T18044<xref ref-type="table-fn" rid="TFN5">+</xref> (M, 4 yr)</td>
            <td align="left" rowspan="1" colspan="1">
              <italic>MEF2C</italic>
            </td>
            <td align="left" rowspan="1" colspan="1">*464Sext*?</td>
            <td align="left" rowspan="1" colspan="1">EE</td>
            <td align="left" rowspan="1" colspan="1">H (4 mth) Ab, At, focal, IS, MJ, TC</td>
            <td align="left" rowspan="1" colspan="1">Mod Hyps, MFD</td>
            <td align="left" rowspan="1" colspan="1">Normal</td>
            <td align="left" rowspan="1" colspan="1">ID (no)</td>
          </tr>
          <tr>
            <td align="left" colspan="2" rowspan="1">
              <bold>Likely pathogenic</bold>
            </td>
            <td align="left" rowspan="1" colspan="1"/>
            <td align="left" rowspan="1" colspan="1"/>
            <td align="left" rowspan="1" colspan="1"/>
            <td align="left" rowspan="1" colspan="1"/>
            <td align="left" rowspan="1" colspan="1"/>
            <td align="left" rowspan="1" colspan="1"/>
          </tr>
          <tr>
            <td align="left" rowspan="1" colspan="1">T19988<xref ref-type="table-fn" rid="TFN5">+</xref> (M, 18 yr)</td>
            <td align="left" rowspan="1" colspan="1">
              <italic>SYNGAP1</italic>
            </td>
            <td align="left" rowspan="1" colspan="1">Lys108Valfs*25</td>
            <td align="left" rowspan="1" colspan="1">EE</td>
            <td align="left" rowspan="1" colspan="1">Unk (in foster care) FDS</td>
            <td align="left" rowspan="1" colspan="1">MFD, DS</td>
            <td align="left" rowspan="1" colspan="1">Unk</td>
            <td align="left" rowspan="1" colspan="1">Moderate ID ASD (unk)</td>
          </tr>
          <tr>
            <td align="left" rowspan="1" colspan="1">T15924<xref ref-type="table-fn" rid="TFN6">#</xref> (M, 11 yr)</td>
            <td align="left" rowspan="1" colspan="1">
              <italic>SYNGAP1</italic>
            </td>
            <td align="left" rowspan="1" colspan="1">Unk (c.389-2A&gt;T)</td>
            <td align="left" rowspan="1" colspan="1">EE</td>
            <td align="left" rowspan="1" colspan="1">Ab (6mth) TC</td>
            <td align="left" rowspan="1" colspan="1">GSW, GPSW, MFD</td>
            <td align="left" rowspan="1" colspan="1">Delayed</td>
            <td align="left" rowspan="1" colspan="1">Severe ID, ASD (yes)</td>
          </tr>
          <tr>
            <td align="left" rowspan="1" colspan="1">T22387<xref ref-type="table-fn" rid="TFN5">+</xref> (F, 7 yr)</td>
            <td align="left" rowspan="1" colspan="1">
              <italic>SYNGAP1</italic>
            </td>
            <td align="left" rowspan="1" colspan="1">Arg143*</td>
            <td align="left" rowspan="1" colspan="1">EE</td>
            <td align="left" rowspan="1" colspan="1">Ab(10mth) MJ</td>
            <td align="left" rowspan="1" colspan="1">GSW</td>
            <td align="left" rowspan="1" colspan="1">Delayed</td>
            <td align="left" rowspan="1" colspan="1">Severe ID, ASD (yes)</td>
          </tr>
          <tr>
            <td align="left" rowspan="1" colspan="1">T162<xref ref-type="table-fn" rid="TFN6">#</xref> (M, 33 yrs)</td>
            <td align="left" rowspan="1" colspan="1">
              <italic>HNRNPU</italic>
            </td>
            <td align="left" rowspan="1" colspan="1">Tyr805*</td>
            <td align="left" rowspan="1" colspan="1">LGS</td>
            <td align="left" rowspan="1" colspan="1">At (2 y) aAb, MJ, NCS, T, TC</td>
            <td align="left" rowspan="1" colspan="1">GSW, GPSW, DS, SSW, GPFA</td>
            <td align="left" rowspan="1" colspan="1">Delayed</td>
            <td align="left" rowspan="1" colspan="1">Severe ID (yes)</td>
          </tr>
        </tbody>
      </table>
      <table-wrap-foot>
        <fn id="TFN3">
          <label>&amp;</label>
          <p id="P43">Polyphen and SIFT scores given for missense variants only.</p>
        </fn>
        <fn id="TFN4">
          <label>$</label>
          <p id="P44">Initial seizure listed first (age of onset, mth â months, y - years), subsequent seizure types. M- male F-female.</p>
        </fn>
        <fn id="TFN5">
          <label>+</label>
          <p id="P45">Parents unavailable,</p>
        </fn>
        <fn id="TFN6">
          <label>#</label>
          <p id="P46">father unavailable.</p>
        </fn>
        <fn id="TFN7">
          <p id="P47">Accession numbers: <italic>CHD2</italic>, NM_001271.3, NP_001262.3; <italic>SYNGAP1</italic>, NM_006772.2, NP_006763.2; <italic>MBD5</italic>, NM_018328.4, NP_060798.2; <italic>GABRG2</italic>, NM_000816.3, NP_000807.2; <italic>MEF2C</italic>, NM_002397.4, NP_002388.2; <italic>HNRNPU</italic>, NM_031844.2, NP_114032.2.</p>
        </fn>
        <fn id="TFN8">
          <p id="P48">EE = Epileptic encephalopathy; LGS = Lennox Gastaut syndrome; MAE = Myoclonic atonic epilepsy. aAb = atypical absence; Ab = absence; At = atonic; FDS = focal dyscognitive seizures; FS = febrile seizures; H = hemiclonic; IS = infantile spasms; MJ = myoclonic jerks; NCS = non-convulsive status epilepticus; SE = status epilepticus; T = tonic; TC = tonic-clonic; DS = Diffuse Slowing; ED = epileptiform discharge; GPFA = Generalised Paroxysmal Fast Activity; GPSW = Generalised Polyspike Wave; GSW = Generalised Spike Wave; Hz = Hertz; MFD = Multi-Focal Discharges; PPR = Photoparoxysmal Response</p>
        </fn>
      </table-wrap-foot>
    </table-wrap>
    <table-wrap id="T3" position="float" orientation="landscape">
      <label>Table 3</label>
      <caption>
        <p id="P49">Pathogenic variants in known epileptic encephalopathy genes</p>
      </caption>
      <table frame="box" rules="all">
        <thead>
          <tr>
            <th align="center" valign="top" rowspan="1" colspan="1">Gene</th>
            <th align="left" rowspan="1" colspan="1">Proband<break/>(Gender)</th>
            <th align="left" valign="top" rowspan="1" colspan="1">Inheritance (inference)</th>
            <th align="left" valign="top" rowspan="1" colspan="1">cDNA change</th>
            <th align="left" valign="top" rowspan="1" colspan="1">Protein change</th>
            <th align="left" valign="top" rowspan="1" colspan="1">Diagnosis</th>
          </tr>
        </thead>
        <tbody>
          <tr>
            <td align="center" rowspan="8" valign="top" colspan="1">
              <italic>SCN1A</italic>
            </td>
            <td align="left" valign="top" rowspan="1" colspan="1">T23445(F)</td>
            <td align="left" valign="top" rowspan="1" colspan="1"><italic>De novo</italic> (P)</td>
            <td align="left" valign="top" rowspan="1" colspan="1">c.4836delC</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Ile1613Phefs*5</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Dravet</td>
          </tr>
          <tr>
            <td align="center" valign="top" rowspan="1" colspan="1">T1639(M)</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Segregates (P)</td>
            <td align="left" valign="top" rowspan="1" colspan="1">c.5962G&gt;A</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Arg1988Trp</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Epilepsy-Aphasia, FS +</td>
          </tr>
          <tr>
            <td align="center" valign="top" rowspan="1" colspan="1">T18466 (M)</td>
            <td align="left" valign="top" rowspan="1" colspan="1"><italic>De novo</italic> (P)</td>
            <td align="left" valign="top" rowspan="1" colspan="1">c.4033G&gt;A</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Pro1345Ser</td>
            <td align="left" valign="top" rowspan="1" colspan="1">EOEE</td>
          </tr>
          <tr>
            <td align="center" valign="top" rowspan="1" colspan="1">T18594 (M)</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Segregates (P) <xref ref-type="table-fn" rid="TFN10">%</xref></td>
            <td align="left" valign="top" rowspan="1" colspan="1">c.133C&gt;T</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Asp45Asn</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Epilepsy-Aphasia, FS +</td>
          </tr>
          <tr>
            <td align="center" valign="top" rowspan="1" colspan="1">T19875 (F)</td>
            <td align="left" valign="top" rowspan="1" colspan="1"><italic>De novo</italic> (P)</td>
            <td align="left" valign="top" rowspan="1" colspan="1">c.3977G&gt;A</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Ala1326Val</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Epilepsy-Aphasia</td>
          </tr>
          <tr>
            <td align="center" valign="top" rowspan="1" colspan="1">T18775 (M)</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Segregates (P) <xref ref-type="table-fn" rid="TFN10">%</xref></td>
            <td align="left" valign="top" rowspan="1" colspan="1">c.1076T&gt;G</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Asn359Thr</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Dravet (ICEGTC) <sup><xref rid="R29" ref-type="bibr">29</xref></sup></td>
          </tr>
          <tr>
            <td align="center" valign="top" rowspan="1" colspan="1">T18997 (M)</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Unk, parents unavailable (LP)</td>
            <td align="left" valign="top" rowspan="1" colspan="1">c.1209delA</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Phe403Leufs*12</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Dravet</td>
          </tr>
          <tr>
            <td align="center" valign="top" rowspan="1" colspan="1">T19963 (M)</td>
            <td align="left" valign="top" rowspan="1" colspan="1"><italic>De novo</italic> (P)</td>
            <td align="left" valign="top" rowspan="1" colspan="1">c.4453T&gt;C</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Asn1485Asp</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Dravet</td>
          </tr>
          <tr>
            <td align="center" rowspan="5" valign="top" colspan="1">
              <italic>SCN2A</italic>
            </td>
            <td align="left" valign="top" rowspan="1" colspan="1">T20632 (M)</td>
            <td align="left" valign="top" rowspan="1" colspan="1"><italic>De novo</italic> (P)</td>
            <td align="left" valign="top" rowspan="1" colspan="1">c.408G&gt;T</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Met136Ile</td>
            <td align="left" valign="top" rowspan="1" colspan="1">EOEE evolving to IS</td>
          </tr>
          <tr>
            <td align="center" valign="top" rowspan="1" colspan="1">T21005 (F)</td>
            <td align="left" valign="top" rowspan="1" colspan="1"><italic>De novo</italic> (P)</td>
            <td align="left" valign="top" rowspan="1" colspan="1">c.2715G&gt;C</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Lys905Asn</td>
            <td align="left" valign="top" rowspan="1" colspan="1">EE</td>
          </tr>
          <tr>
            <td align="center" valign="top" rowspan="1" colspan="1">T22816(F)</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Unk, father unavailable (LP)</td>
            <td align="left" valign="top" rowspan="1" colspan="1">c.2783T&gt;G</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Phe928Cys<xref ref-type="table-fn" rid="TFN11">#</xref></td>
            <td align="left" valign="top" rowspan="1" colspan="1">EE</td>
          </tr>
          <tr>
            <td align="center" valign="top" rowspan="1" colspan="1">T20340 (F)</td>
            <td align="left" valign="top" rowspan="1" colspan="1"><italic>De novo</italic> (P)</td>
            <td align="left" valign="top" rowspan="1" colspan="1">c.1154delC</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Ile1021Tyrfs*16</td>
            <td align="left" valign="top" rowspan="1" colspan="1">LGS</td>
          </tr>
          <tr>
            <td align="center" valign="top" rowspan="1" colspan="1">T24127 (F)</td>
            <td align="left" valign="top" rowspan="1" colspan="1"><italic>De novo</italic> (P)</td>
            <td align="left" valign="top" rowspan="1" colspan="1">c.5645G&gt;A</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Arg1882Gln</td>
            <td align="left" valign="top" rowspan="1" colspan="1">EE</td>
          </tr>
          <tr>
            <td align="center" rowspan="2" valign="top" colspan="1">
              <italic>PCDH19</italic>
            </td>
            <td align="left" valign="top" rowspan="1" colspan="1">T23579 (F)</td>
            <td align="left" valign="top" rowspan="1" colspan="1">X-linked, female restricted (P)</td>
            <td align="left" valign="top" rowspan="1" colspan="1">c.1681G&gt;A</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Pro561Ser</td>
            <td align="left" valign="top" rowspan="1" colspan="1">EE</td>
          </tr>
          <tr>
            <td align="center" valign="top" rowspan="1" colspan="1">T23305 (F)</td>
            <td align="left" valign="top" rowspan="1" colspan="1">X-linked, female restricted (P)</td>
            <td align="left" valign="top" rowspan="1" colspan="1">c.2873C&gt;T</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Arg958Gln</td>
            <td align="left" valign="top" rowspan="1" colspan="1">LGS</td>
          </tr>
          <tr>
            <td align="center" rowspan="8" valign="top" colspan="1">
              <italic>CDKL5</italic>
            </td>
            <td align="left" valign="top" rowspan="1" colspan="1">T20819 (M)</td>
            <td align="left" valign="top" rowspan="1" colspan="1"><italic>De novo</italic> (P)</td>
            <td align="left" valign="top" rowspan="1" colspan="1">c.464-2A&gt;G</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Unk</td>
            <td align="left" valign="top" rowspan="1" colspan="1">EOEE</td>
          </tr>
          <tr>
            <td align="center" valign="top" rowspan="1" colspan="1">T22724 (M)</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Inherited from unaffected mother, X-linked (P)</td>
            <td align="left" valign="top" rowspan="1" colspan="1">c.433C&gt;T</td>
            <td align="left" valign="top" rowspan="1" colspan="1">His145Tyr</td>
            <td align="left" valign="top" rowspan="1" colspan="1">EE</td>
          </tr>
          <tr>
            <td align="center" valign="top" rowspan="1" colspan="1">T22954 (F)</td>
            <td align="left" valign="top" rowspan="1" colspan="1"><italic>De novo</italic> (P)</td>
            <td align="left" valign="top" rowspan="1" colspan="1">c.545T&gt;C</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Leu182Pro</td>
            <td align="left" valign="top" rowspan="1" colspan="1">EOEE</td>
          </tr>
          <tr>
            <td align="center" valign="top" rowspan="1" colspan="1">T897(F)</td>
            <td align="left" valign="top" rowspan="1" colspan="1"><italic>De novo</italic> (P)</td>
            <td align="left" valign="top" rowspan="1" colspan="1">c.2564C&gt;G</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Ser855*</td>
            <td align="left" valign="top" rowspan="1" colspan="1">IS</td>
          </tr>
          <tr>
            <td align="center" valign="top" rowspan="1" colspan="1">T23057 (M)</td>
            <td align="left" valign="top" rowspan="1" colspan="1"><italic>De novo</italic> (P)</td>
            <td align="left" valign="top" rowspan="1" colspan="1">c.1926delT</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Leu642Argfs*16</td>
            <td align="left" valign="top" rowspan="1" colspan="1">IS</td>
          </tr>
          <tr>
            <td align="center" valign="top" rowspan="1" colspan="1">T23951 (M)</td>
            <td align="left" valign="top" rowspan="1" colspan="1"><italic>De novo</italic> (P)</td>
            <td align="left" valign="top" rowspan="1" colspan="1">c.533G&gt;A</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Arg178Gln</td>
            <td align="left" valign="top" rowspan="1" colspan="1">EOEE</td>
          </tr>
          <tr>
            <td align="center" valign="top" rowspan="1" colspan="1">T23234 (F)</td>
            <td align="left" valign="top" rowspan="1" colspan="1"><italic>De novo</italic> (P)</td>
            <td align="left" valign="top" rowspan="1" colspan="1">c.620G&gt;A</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Gly207Glu</td>
            <td align="left" valign="top" rowspan="1" colspan="1">EE</td>
          </tr>
          <tr>
            <td align="center" valign="top" rowspan="1" colspan="1">T24139 (M)</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Unk, parents unavailable (LP)</td>
            <td align="left" valign="top" rowspan="1" colspan="1">c.1926delT</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Leu642Argfs*16</td>
            <td align="left" valign="top" rowspan="1" colspan="1">EOEE</td>
          </tr>
          <tr>
            <td align="center" rowspan="7" valign="top" colspan="1">
              <italic>STXBP1</italic>
            </td>
            <td align="left" valign="top" rowspan="1" colspan="1">T22595 (M)</td>
            <td align="left" valign="top" rowspan="1" colspan="1"><italic>De novo</italic> (P)</td>
            <td align="left" valign="top" rowspan="1" colspan="1">c.1154delC</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Met387Tyrfs*17</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Ohtahara</td>
          </tr>
          <tr>
            <td align="center" valign="top" rowspan="1" colspan="1">T1266 (M)</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Unk, mother unavailable (LP)</td>
            <td align="left" valign="top" rowspan="1" colspan="1">c.1630G&gt;T</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Gly544Cys<xref ref-type="table-fn" rid="TFN11">#</xref></td>
            <td align="left" valign="top" rowspan="1" colspan="1">LGS</td>
          </tr>
          <tr>
            <td align="center" valign="top" rowspan="1" colspan="1">T23151 (F)</td>
            <td align="left" valign="top" rowspan="1" colspan="1"><italic>De novo</italic> (P)</td>
            <td align="left" valign="top" rowspan="1" colspan="1">c.125C&gt;T</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Ser42Phe</td>
            <td align="left" valign="top" rowspan="1" colspan="1">EOEE</td>
          </tr>
          <tr>
            <td align="center" valign="top" rowspan="1" colspan="1">T23553 (F)</td>
            <td align="left" valign="top" rowspan="1" colspan="1"><italic>De novo</italic> (P)</td>
            <td align="left" valign="top" rowspan="1" colspan="1">c.238T&gt;C</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Ser80Pro</td>
            <td align="left" valign="top" rowspan="1" colspan="1">EE</td>
          </tr>
          <tr>
            <td align="center" valign="top" rowspan="1" colspan="1">T23122 (M)</td>
            <td align="left" valign="top" rowspan="1" colspan="1"><italic>De novo</italic> (P)</td>
            <td align="left" valign="top" rowspan="1" colspan="1">c.568C&gt;T</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Arg190Trp</td>
            <td align="left" valign="top" rowspan="1" colspan="1">EOEE</td>
          </tr>
          <tr>
            <td align="center" valign="top" rowspan="1" colspan="1">T22856 (M)</td>
            <td align="left" valign="top" rowspan="1" colspan="1"><italic>De novo</italic> (P)</td>
            <td align="left" valign="top" rowspan="1" colspan="1">c.1060T&gt;C</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Cys354Arg</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Ohtahara</td>
          </tr>
          <tr>
            <td align="center" valign="top" rowspan="1" colspan="1">T23289 (M)</td>
            <td align="left" valign="top" rowspan="1" colspan="1"><italic>De novo</italic> (P)</td>
            <td align="left" valign="top" rowspan="1" colspan="1">c.1708G&gt;A</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Thr570Ala</td>
            <td align="left" valign="top" rowspan="1" colspan="1">EE</td>
          </tr>
          <tr>
            <td align="center" valign="top" rowspan="1" colspan="1">
              <italic>UBE3A</italic>
            </td>
            <td align="left" valign="top" rowspan="1" colspan="1">T23859 (F)</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Inherited from unaffected mother, affected sib also mutation positive (P)</td>
            <td align="left" valign="top" rowspan="1" colspan="1">c.1585G&gt;A</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Arg506Cys<xref ref-type="table-fn" rid="TFN12">&amp;</xref></td>
            <td align="left" valign="top" rowspan="1" colspan="1">EE â features suggestive of Angelman syndrome</td>
          </tr>
          <tr>
            <td align="center" valign="top" rowspan="1" colspan="1">
              <italic>SCN8A</italic>
            </td>
            <td align="left" valign="top" rowspan="1" colspan="1">T3929 (M)</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Inherited from somatic mosaic father <xref ref-type="table-fn" rid="TFN13">@</xref> (P)</td>
            <td align="left" valign="top" rowspan="1" colspan="1">c.3868C&gt;G</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Leu1290Val</td>
            <td align="left" valign="top" rowspan="1" colspan="1">EE</td>
          </tr>
          <tr>
            <td align="center" rowspan="2" valign="top" colspan="1">
              <italic>KCNQ2</italic>
            </td>
            <td align="left" valign="top" rowspan="1" colspan="1">T24158 (M)</td>
            <td align="left" valign="top" rowspan="1" colspan="1"><italic>De novo</italic> (P)</td>
            <td align="left" valign="top" rowspan="1" colspan="1">c.587G&gt;A</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Ala196Val</td>
            <td align="left" valign="top" rowspan="1" colspan="1">EOEE</td>
          </tr>
          <tr>
            <td align="center" valign="top" rowspan="1" colspan="1">T23919 (F)</td>
            <td align="left" valign="top" rowspan="1" colspan="1"><italic>De novo</italic> (P)</td>
            <td align="left" valign="top" rowspan="1" colspan="1">c.602C&gt;T</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Arg201His</td>
            <td align="left" valign="top" rowspan="1" colspan="1">EOEE/IS</td>
          </tr>
          <tr>
            <td align="center" valign="top" rowspan="1" colspan="1">
              <italic>PNPO</italic>
            </td>
            <td align="left" valign="top" rowspan="1" colspan="1">T23451 (M)</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Homozygous recessive (P)</td>
            <td align="left" valign="top" rowspan="1" colspan="1">c.686G&gt;A</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Arg229Gln<xref ref-type="table-fn" rid="TFN14">^</xref></td>
            <td align="left" valign="top" rowspan="1" colspan="1">EME</td>
          </tr>
          <tr>
            <td align="center" valign="top" rowspan="1" colspan="1">
              <italic>PNKP</italic>
            </td>
            <td align="left" valign="top" rowspan="1" colspan="1">T23141<bold/> (M)</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Homozygous recessive (P)</td>
            <td align="left" valign="top" rowspan="1" colspan="1">c.58G&gt;A</td>
            <td align="left" valign="top" rowspan="1" colspan="1">Pro20Ser</td>
            <td align="left" valign="top" rowspan="1" colspan="1">EE</td>
          </tr>
        </tbody>
      </table>
      <table-wrap-foot>
        <fn id="TFN9">
          <p id="P50">M- male F-female; P â pathogenic, LP â likely pathogenic;</p>
        </fn>
        <fn id="TFN10">
          <label>%</label>
          <p id="P51">variant segregates with the disorder, pedigrees <xref ref-type="supplementary-material" rid="SD1">Supplementary Figure 5</xref>;</p>
        </fn>
        <fn id="TFN11">
          <label>#</label>
          <p id="P52">Two missense variants likely pathogenic (see methods);</p>
        </fn>
        <fn id="TFN12">
          <label>&amp;</label>
          <p id="P53">known pathogenic variant <sup><xref rid="R30" ref-type="bibr">30</xref></sup>,</p>
        </fn>
        <fn id="TFN13">
          <label>@</label>
          <p id="P54">father is somatic mosaic, with 13% of cells carrying alternate, pathogenic allele;</p>
        </fn>
        <fn id="TFN14">
          <label>^</label>
          <p id="P55">known pathogenic variant dbSNP:rs104894629 <sup><xref rid="R31" ref-type="bibr">31</xref></sup>.</p>
        </fn>
        <fn id="TFN15">
          <p id="P56">Accession numbers: <italic>SCN1A,</italic> NM_001165963.1, NP_001159435.1; <italic>SCN2A,</italic> NM_021007.2, NP_066287.2; <italic>PCDH19,</italic> NM_001184880.1, NP_001171809.1; <italic>CDKL5,</italic> NM_001037343.1, NP_001032420.1; <italic>STXBP1,</italic> NP_003165.3, NM_ 001032221.3; <italic>UBE3A</italic>, NM_000462.3, NP_000453.2; <italic>SCN8A,</italic> NM_001177984.2; NP_001171455.1; <italic>KCNQ2,</italic> NM_004518.4, NP_004509.2; <italic>PNPO,</italic> NM018129.3, NP_060599.1;<italic>PNKP</italic>, NM_007254.3, NP009185.2</p>
        </fn>
        <fn id="TFN16">
          <p id="P57">EE = epileptic encephalopathy not otherwise specified: EOEE = early onset epileptic encephalopathy; EME = early myoclonic encephalopathy; FS + = febrile seizures plus; ICEGTC = intractable childhood epilepsy with generalized tonic clonic seizures; LGS = Lennox Gastaut syndrome; IS = Infantile spasms, Unk = unknown</p>
        </fn>
      </table-wrap-foot>
    </table-wrap>
  </floats-group>
</article>

</metadata></record></GetRecord></OAI-PMH>